AI investment accelerates into chronic care, home health, and workforce training in 2026

The three investment segments identified in the MarketScale analysis share a common logic: each addresses a structural healthcare demand that is clearly growing and where AI creates a credible efficiency argument with enterprise buyers.

Chronic disease management is the largest and most heterogeneous category. The GLP-1 moment has been particularly significant: weight-management medications that require ongoing monitoring, dose adjustment, and side-effect management have created demand for AI-enabled care management platforms that can support the monitoring burden at scale without proportional increases in clinician time. Platforms that integrate cardiometabolic monitoring (weight, blood pressure, glucose, lipids), medication management, and behavioral coaching are attracting investment as the number of GLP-1 patients grows.

AI-enabled home health investment is following the care-site-shift trend: as payers and patients push more care out of expensive acute-care settings, the clinical infrastructure for home-based care needs to scale. Remote patient monitoring generates data volumes that home health nurses cannot review manually; AI summarization that surfaces actionable signals from continuous monitoring is an operational necessity rather than a luxury at scale.

Workforce training tools are the least flashy but perhaps most structurally important category. The clinician shortage — particularly in nursing, primary care, behavioral health, and medical imaging — is not going to be solved by AI that replaces clinicians. It may be partially addressed by AI that helps existing clinicians train the next generation faster, helps newly-qualified clinicians develop expertise more rapidly, and helps clinical educators identify where trainees need additional support. The case-based learning and simulation platforms that AI enables are attracting investment from both traditional education companies and health-system venture arms.